Downgrades Buy Neutral X

LIVN LivaNova

Goldman

$55

Upgrades Peer Perform Outperform X

LIVN LivaNova

Wolfe Research

$60

Downgrades Outperform Peer Perform X

LIVN LivaNova

Wolfe Research

Initiated Buy X

LIVN LivaNova

Goldman

$65

Upgrades Neutral Outperform X

LIVN LivaNova

Robert W. Baird

$55 $66

Reiterated Buy X

LIVN LivaNova

Needham

Upgrades Neutral Buy X

LIVN LivaNova

Mizuho

$60 $70

Initiated Hold X

LIVN LivaNova

HSBC Securities

$52

Initiated Neutral X

LIVN LivaNova

Robert W. Baird

$56

Initiated Neutral X

LIVN LivaNova

Mizuho

$48

Initiated Equal Weight X

LIVN LivaNova

Barclays

$62

Upgrades Hold Buy X

LIVN LivaNova

Needham

$93

Downgrades Buy Hold X

LIVN LivaNova

Berenberg

$84

Downgrades Buy Hold X

LIVN LivaNova

Needham

Reiterated Buy X

LIVN LivaNova

Needham

$135 $120

Initiated Neutral X

LIVN LivaNova

UBS

$105

Reiterated Buy X

LIVN LivaNova

Needham

$128 $135

Initiated Buy X

LIVN LivaNova

Stifel

$115

Reiterated Buy X

LIVN LivaNova

Needham

$102 $106

LIVN  LivaNova PLC

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.